Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 <scp>IgG‐Positive NMOSD</scp>

Abstract

This analysis demonstrates that eculizumab's long-term safety profile in NMOSD is consistent with its established profile across other indications. This analysis also demonstrated the sustained ability of long-term eculizumab treatment to reduce relapse risk in patients with AQP4-IgG+ NMOSD. ANN NEUROL 2021;89:1088-1098.